PJSC “Indar” (Kiev), producer of insulin by the end of 2021, has increased its net profit by 6.4 times from 117 thousand UAH in 2020 to 744 thousand UAH.
According to the system of information disclosure of the National Commission on Securities and Stock Market (NKTSBFR), the company’s net profit in 2021 increased almost 1.3 times compared to 2020 – up to 753.184 million UAH.
As reported, “Indar” (Kiev) in 2020 reduced net profit by more than 370 times from 43.017 million UAH in 2019 to 117 thousand UAH. Net income from sales of the company in 2020 decreased 1.6 times compared to 2019 – to 591.543 million UAH.
PJSC “Indar”, created by the decision of the Cabinet of Ministers of Ukraine in 1997 on the basis of Kiev meat processing plant, is a subsidiary of the state company PJSC “Ukrmedprom”, which owns 70.7% of the total number of shares. Another 29.3% of the company belongs to Luraq investments limited (Cyprus).
The manufacturer is included in the list of state-owned objects of strategic importance to the economy and security of the state and is a member of the association “Drug Manufacturers of Ukraine”.
